Purchase Order 75N98024P02678

Award Date 8/9/24
Potential Completion Date 9/30/24
Potential Value $12K
Funding Federal Agency
National Eye Institute
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Great Britain, United Kingdom
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price purchase order contract, valued at $12,369.70, was awarded by the National Institute on Aging (NIA), a component of the National Institutes of Health (NIH), to UK Biobank Limited, a non-profit organization. The contract provides Tier 3 access to UK Biobank's large-scale, de-identified biomedical database containing genetic, lifestyle, and health information from over 500,000 participants in the United Kingdom. This data access supports biomedical research projects across...
This federal contract award, valued at $11,550.24, was issued by the National Human Genome Research Institute, a civilian agency within the National Institutes of Health (NIH), to UK Biobank Limited, a non-profit organization based in the United Kingdom. The contract is for a 36-month extension to provide Tier 3 level access to UK Biobank's large-scale biomedical database, which contains de-identified genetic, lifestyle, and health information from over 500,000 participants in the UK. This...
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, has awarded a $12,000 firm fixed price purchase order to UK Biobank Limited. The purpose of this contract is to provide Dr. Stewart and his team access to biobank data including whole exome and genome data on 500,000 individuals linked to electronic health records within UK Biobank. This will support analysis of the frequency, phenotypic spectrum, and penetrance...
This purchase order awards UK Biobank Limited $12,934.99 to provide Tier 3 access fees under a potential value of the same amount. As a non-profit organization, the contractor will deliver its standard biobank datasets and related laboratory and testing services to the Department of Health and Human Services' National Institutes of Health National Human Genome Research Institute in Bethesda, Maryland by November 14, 2024. The firm fixed price contract vehicle was awarded on November 15, 2023...
UK Biobank Limited has been awarded a $13,500 purchase order by the National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, to provide laboratory and testing services. The firm fixed price contract runs from December 2023 through March 2026 and will be performed by UK Biobank in Great Britain. No additional details were provided on the original solicitation or work scope. The award does not appear to be associated with a...
The University of Exeter has been awarded a $546,052 firm fixed-price purchase order by the National Institutes of Health National Institute on Aging to provide epidemiology and statistical analysis services supporting a research project utilizing United Kingdom Biobank data. The solicitation sought quotations for two epidemiologists/statisticians and one postdoctoral scholar experienced in analyzing UK Biobank data to develop analysis plans, perform statistical analyses, and interpret...
Bit Bio Limited has been awarded a $85,813.50 firm fixed price purchase order by the National Institutes of Health's National Institute of Environmental Health Sciences to provide unspecified services from September 30, 2023 through November 30, 2023 in Great Britain. As a component of the U.S. Department of Health and Human Services, the National Institute of Environmental Health Sciences conducts research on how the environment affects human health. No additional information is provided on...
This is a $23,911,812.33 cost reimbursable contract awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to the University of Maryland, Baltimore (UMB) to operate the NIH NeuroBioBank and Tissue Repository. The contract does not have a set-aside designation. The NeuroBioBank collects, stores, and distributes human brain tissue and other biospecimens to researchers studying neurological, psychiatric, and neurodevelopmental disorders. UMB,...
This is a $5,431,782.00 cost-plus-fixed-fee definitive contract awarded by the National Institute on Aging (NIA), part of the Department of Health and Human Services, to Information Management Services, Inc. (IMS) for data coordination and systems management services to support the NIA Biobank program. The contract has a period of performance from August 30, 2023 through August 29, 2028. This requirement aims to provide continuity of existing services, improve those services, and expand the...
The National Eye Institute (NEI), a civilian agency under the National Institutes of Health (NIH), awarded a $92,160 firm-fixed-price purchase order to Diagenode, LLC, a global life sciences company specializing in epigenetics research and laboratory services. The contract is for genome-wide methylation services, which are essential to the completion of AMD and Aging projects currently underway at the NEI. Diagenode was sole-sourced for this requirement as they can provide the required...

This firm fixed-price purchase order contract was awarded by the National Eye Institute (NEI), a component of the National Institutes of Health (NIH), to UK Biobank Limited, a non-profit organization. The $11,630.34 contract provides access to UK Biobank's large-scale biomedical database containing genetic, lifestyle, and health information from over 500,000 UK participants. This biobank serves as a research resource for approved scientific studies, and the contract facilitates projects focused on analyzing pathogenic variants associated with various diseases and conditions, including age-related diseases, heart/lung/blood disorders, cancer, alcoholism, and mental health. The contract has a performance period ending on September 30, 2024 and does not include any set-aside designations.

Generated 8/11/24, 9:08 AM